Resmed's AirTouch N30i Nasal Cradle Mask Wins Two 2025 Red Dot Awards for Innovative Design and Medical Excellence

Resmed's AirTouch N30i mask won two Red Dot Awards for its innovative design and comfort in CPAP therapy.

Quiver AI Summary

Resmed has announced that its AirTouch™ N30i nasal cradle mask has won two Red Dot Awards for Product Design 2025 in the categories of Innovative Products and Medical Design & Healthcare. Launched in October 2024, the mask features a unique fabric-silicone cushion that enhances comfort and ease of use for CPAP therapy, aiming to improve adherence in patients with obstructive sleep apnea, a condition affecting over a billion people globally. It boasts innovative design elements such as a soft, breathable fabric frame and a top-of-head hose connection for better movement during sleep. In user studies, the AirTouch N30i received high ratings for comfort compared to traditional masks. This award recognition highlights Resmed's commitment to combining clinical performance with user-friendly design, aiming to improve health outcomes for patients. This achievement adds to Resmed's significant portfolio of patents, showcasing its leadership in sleep and respiratory care technologies.

Potential Positives

Resmed's AirTouch™ N30i nasal cradle mask won two prestigious Red Dot Awards, enhancing the company's reputation for innovative product design in the health technology field.
The mask's unique features, such as the ComfiSoft™ fabric cushion and breathable design, were positively received in a clinical study, achieving a perfect satisfaction rating from experienced CPAP users.
With a portfolio of 10,000 patents and designs, Resmed demonstrates significant investment in innovation and leadership in the sleep and respiratory care market.
Recognition by independent panels for excellence in design can aid in market differentiation and attract both patients and healthcare providers to Resmed’s products.

Potential Negatives

Despite the positive recognition, the press release does not address any potential criticisms or drawbacks of the AirTouch N30i mask, which could raise concerns about transparency to consumers.
The extensive focus on awards may divert attention from clinical efficacy data or long-term performance of the product, which are critical for consumer trust.
The acknowledgment of one billion people affected by obstructive sleep apnea raises questions about the accessibility and affordability of the AirTouch N30i for this large population, which is not addressed in the release.

FAQ

What awards has the AirTouch N30i mask received?

The AirTouch N30i mask won two Red Dot Awards for Product Design 2025 in Innovative Products and Medical Design & Healthcare categories.

What is special about the design of AirTouch N30i?

The mask features a unique nasal cushion made from fabric fused with silicone, enhancing comfort and clinical performance.

How does AirTouch N30i improve patient experience with CPAP therapy?

Its design provides a softer, more breathable experience, making it easier for patients to start and adhere to CPAP therapy.

What other design awards has Resmed won?

In addition to the Red Dot Awards, the AirTouch N30i also received the Australian Good Design Award in the Product Medical category.

How does Resmed support patients with sleep apnea?

Resmed creates innovative technologies like the AirTouch N30i to improve adherence to therapy, enhancing overall health outcomes for patients.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$RMD Congressional Stock Trading

Members of Congress have traded $RMD stock 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.

Here’s a breakdown of recent trading of $RMD stock by members of Congress over the last 6 months:

REPRESENTATIVE KELLY MORRISON has traded it 5 times. They made 0 purchases and 5 sales worth up to $75,000 on 06/04, 04/28.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$RMD Insider Trading Activity

$RMD insiders have traded $RMD stock on the open market 29 times in the past 6 months. Of those trades, 0 have been purchases and 29 have been sales.

Here’s a breakdown of recent trading of $RMD stock by insiders over the last 6 months:

MICHAEL J. FARRELL (Chief Executive Officer) has made 0 purchases and 6 sales selling 48,054 shares for an estimated $11,770,759.
KAUSHIK GHOSHAL (Chief Commercial Officer, SaaS) has made 0 purchases and 5 sales selling 18,858 shares for an estimated $4,477,282.
BRETT SANDERCOCK (Chief Financial Officer) has made 0 purchases and 6 sales selling 13,527 shares for an estimated $3,424,598.
PETER C FARRELL has made 0 purchases and 5 sales selling 8,945 shares for an estimated $2,115,478.
JOHN HERNANDEZ sold 2,575 shares for an estimated $739,289
WITTE JAN DE sold 2,000 shares for an estimated $486,940
MICHAEL J RIDER (Global General Counsel) has made 0 purchases and 5 sales selling 285 shares for an estimated $70,296.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$RMD Hedge Fund Activity

We have seen 458 institutional investors add shares of $RMD stock to their portfolio, and 453 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MORGAN STANLEY removed 1,479,378 shares (-35.7%) from their portfolio in Q2 2025, for an estimated $381,679,524
GAMMA INVESTING LLC removed 729,713 shares (-99.5%) from their portfolio in Q2 2025, for an estimated $188,265,954
NORGES BANK added 669,170 shares (+129.0%) to their portfolio in Q2 2025, for an estimated $172,645,860
OVERSEA-CHINESE BANKING CORP LTD removed 547,532 shares (-92.7%) from their portfolio in Q2 2025, for an estimated $141,263,256
MARSHALL WACE, LLP removed 543,857 shares (-97.7%) from their portfolio in Q2 2025, for an estimated $140,315,106
CONGRESS ASSET MANAGEMENT CO removed 484,773 shares (-99.0%) from their portfolio in Q2 2025, for an estimated $125,071,434
CITADEL ADVISORS LLC added 328,864 shares (+853.5%) to their portfolio in Q2 2025, for an estimated $84,846,912

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$RMD Analyst Ratings

Wall Street analysts have issued reports on $RMD in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Mizuho issued a "Outperform" rating on 08/01/2025
RBC Capital issued a "Outperform" rating on 08/01/2025
UBS issued a "Buy" rating on 08/01/2025
JP Morgan issued a "Overweight" rating on 04/24/2025
Keybanc issued a "Overweight" rating on 04/24/2025
Citigroup issued a "Buy" rating on 03/05/2025

To track analyst ratings and price targets for $RMD, check out Quiver Quantitative's $RMD forecast page.

$RMD Price Targets

Multiple analysts have issued price targets for $RMD recently. We have seen 8 analysts offer price targets for $RMD in the last 6 months, with a median target of $290.0.

Here are some recent targets:

Brett Fishbin from Keybanc set a target price of $298.0 on 08/01/2025
Adam Maeder from Piper Sandler set a target price of $270.0 on 08/01/2025
Jonathan Block from Stifel set a target price of $270.0 on 08/01/2025
Craig Wong-Pan from RBC Capital set a target price of $300.0 on 08/01/2025
Laura Sutcliffe from UBS set a target price of $325.0 on 08/01/2025
Anthony Petrone from Mizuho set a target price of $290.0 on 08/01/2025
David Low from JP Morgan set a target price of $290.0 on 04/24/2025

Full Release

SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced that its AirTouch™ N30i nasal cradle mask won two prestigious Red Dot Awards : Product Design 2025 in both the Innovative Products and Medical Design & Healthcare categories. The AirTouch N30i features Resmed's first-ever nasal cushion made from fabric fused with silicone, designed to deliver both clinical performance and a therapy experience that feels more natural and comfortable making it easier for people to start and stick with CPAP therapy.

Launched in October 2024, the AirTouch N30i builds on Resmed’s legacy of product leadership. The mask combines Resmed’s patented ComfiSoft™ fabric cushion and a fabric-wrapped frame designed to deliver softness and breathability without sacrificing performance. Its layered design is intended to help release heat and moisture while maintaining a secure seal for effective therapy. As part of Resmed’s Freedom category, it also features a top-of-head hose connection and 360-degree rotating elbow to give users more freedom of movement during sleep.

Obstructive sleep apnea (OSA) affects more than one billion people worldwide ¹ . This chronic condition can significantly disrupt daily life and increase the risk of serious health issues, including high blood pressure, diabetes, heart disease, and stroke ² . Resmed’s innovations, like the AirTouch N30i, are designed to help patients stay on therapy thereby closing gaps in care. In a multi-center study with experienced CPAP users, users rated AirTouch N30i 10 out of 10 for feeling cooler, softer, more breathable, and less sweaty than their own masks ³ .

“At Resmed, we design with the patient experience at the center—where clinical performance and human-centered design intersect,” said Justin Leong, Chief Product Officer at Resmed. “This recognition reinforces our belief that patients shouldn’t have to compromise between therapy efficacy and comfort. When we create technology that patients love to use, we can help drive higher adherence, better outcomes, and ultimately, healthier lives.”

Resmed’s innovation leadership is also reflected in having a global portfolio of 10,000 patents and designs, granted or pending, a milestone that underscores the company’s long-standing leadership in sleep and respiratory care and its investment in technologies that empower patients and providers alike. This achievement also reflects Resmed’s future-focused strategy to drive innovation, protect core solutions, and expand global access by ensuring innovations reach the patients who need them most.

The Red Dot Award is judged by an independent panel of 43 experts from 21 countries. The award honors outstanding products that demonstrate excellence across four dimensions: quality of function, seduction, use, and responsibility.

This is the second major design award for the AirTouch N30i. In September 2024, the mask received the Australian Good Design Award in the Product Medical and Scientific category. This award, one of the longest-running and most prestigious international design programs, celebrates excellence in design that improves quality of life and drives innovation.

About Resmed

Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.

For Media	For Investors
Caela Shay	Salli Schwartz
[email protected]	[email protected]
[email protected]	[email protected]

¹ Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ, Nunez CM, Patel SR, Penzel T, Pépin JL, Peppard PE, Sinha S, Tufik S, Valentine K, Malhotra A. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019 Aug;7(8):687-698. doi: 10.1016/S2213-2600(19)30198-5. Epub 2019 Jul 9. PMID: 31300334; PMCID: PMC7007763
² Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 2021; 144(3): e56-e67.
³ ResMed conducted an external, 90-day, take-home study of the AirTouch N30i mask with 120 adults who had been on PAP therapy for OSA (≥ 6 months) and were using either the AirFit N30i or DreamWear nasal masks. The study took place at two sites in the U.S. from May 31 to November 6, 2023.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/36a89391-bcfb-40b7-9dc4-edf80d2a3d51